JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on June 13, 2003; DOI: 10.1124/jpet.103.053389


0022-3565/03/3063-1050-1057$20.00
JPET 306:1050-1057, 2003
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.053389v1
306/3/1050    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Omelchenko, A.
Right arrow Articles by Hryshko, L. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Omelchenko, A.
Right arrow Articles by Hryshko, L. V.

CARDIOVASCULAR

Inhibition of Canine (NCX1.1) and Drosophila (CALX1.1) Na+-Ca2+ Exchangers by 7-Chloro-3,5-dihydro-5-phenyl-1H-4,1-benzothiazepine-2-one (CGP-37157)

Alexander Omelchenko, Ron Bouchard, Hoa Dinh Le, Platon Choptiany, Neeraj Visen, Mark Hnatowich, and Larry V. Hryshko

Institute of Cardiovascular Sciences, University of Manitoba, Faculty of Medicine, St. Boniface Research Centre, Winnipeg, Manitoba, Canada

The electrophysiological effects of the benzothiazepine 7-chloro-3,5-dihydro-5-phenyl-1H-4,1-benzothiazepine-2-one (CGP-37157) (CGP) were investigated on the canine (NCX1.1) and Drosophila (CALX1.1) plasmalemmal Na+-Ca2+ exchangers. These exchangers were selected for study because they show opposite responses to cytoplasmic regulatory Ca2+, thereby allowing us to examine the role of this regulatory mechanism in the inhibitory effects of CGP. CGP blocked Na+-Ca2+ exchange current mediated by both transporters with moderate potency (IC50 values = ~3-17 µM) compared with other recently reported blockers of Na+-Ca2+ exchange [e.g., 2-[4-[2,5-difluorophenyl) methoxy]phenoxy]phenoxy]-5-ethoxyaniline (KB-R7943) and 2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea (SEA0400)]. Experiments using {alpha}-chymotrypsin to remove autoregulation of Na+-Ca2+ exchange showed that block by CGP was reduced, suggesting that part of the effects of this drug may require intact ionic regulatory mechanisms. For NCX1.1, the inhibition produced by CGP was greater for outward Na+-Ca2+ exchange currents compared with inward currents. When CALX1.1 was examined, the extent of inhibition was similar for both inward and outward exchange currents. Although the extent and potency of CGP-mediated inhibition of Na+-Ca2+ exchange are less than those observed with SEA0400 and KB-R7943, our data demonstrate that CGP constitutes a novel class of plasmalemmal Na+-Ca2+ exchange inhibitors. Moreover, the widespread use of CGP as a selective mitochondrial Na+-Ca2+ exchange inhibitor should be reconsidered in light of these additional inhibitory effects.


Received April 25, 2003; accepted May 27, 2003.

Address correspondence to: Dr. Larry V. Hryshko, Institute of Cardiovascular Sciences, University of Manitoba Faculty of Medicine, St. Boniface Research Centre, 351 Tache Ave., Winnipeg, MB, Canada R2H 2A6. E-mail: lhryshko{at}sbrc.ca




This article has been cited by other articles:


Home page
J. Neurophysiol.Home page
J.-W. Lin, Q. Fu, and T. Allana
Probing the Endogenous Ca2+ Buffers at the Presynaptic Terminals of the Crayfish Neuromuscular Junction
J Neurophysiol, July 1, 2005; 94(1): 377 - 386.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.